Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 25 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				9823 H6Q-MC-JCBJ, PRELUDE, NCT00332202


2.		A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				11183 H6Q-MC-S030, NCT00452413

Last Modified: 12/5/2008 First Published: 10/6/2006


3.		Phase II Randomized Study of Enzastaurin Hydrochloride in Preventing Non-Small Cell Lung Cancer in Former Smokers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				45 and over				NCI, Pharmaceutical / Industry				MCC-14787 MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816


4.		Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				10708 H6Q-MC-S019, NCT00391118


5.		A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				45 and over				Pharmaceutical / Industry				10723 H6Q-MC-S009, NCT00414960


6.		Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				10710 H6Q-MC-S020, NCT00415363


7.		Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				10536 H6Q-MC-S035, NCT00437294


8.		An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				9824 H6Q-MC-S028, NCT00451178


9.		Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				10736 H6Q-MC-S023, NCT00451555


10.		A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				11311 H6Q-MC-S032, NCT00466440

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute